News

News

SARS-CoV-2/Covid-19 Pandemic Update and Commentary

Apr 14, 2020

SARS-CoV-2/Covid-19 Pandemic Update and Commentary By Kevin C. Maki, PhD, CLS, FNLA   Comments from our Chief Scientist, Epidemiologist Kevin C. Maki, PhD as of April 11, 2020   The toll produced by the global pandemic of novel coronavirus (SARS-CoV-2), which causes the Covid-19 disease, is enormous, both in human and economic terms.  I am

Read More

Comparing the Effects of Consuming Egg-based Breakfast Meals, versus Higher Carbohydrate Breakfast Meals, on Cardiometabolic Risk Factors

Apr 14, 2020

Comparing the Effects of Consuming Egg-based Breakfast Meals, versus Higher Carbohydrate Breakfast Meals, on Cardiometabolic Risk Factors By Mary R Dicklin, PhD and Kevin C Maki, PhD, CLS, FNLA   Recently, our group conducted a clinical trial that compared the effects of consuming egg-based breakfast meals with non-egg, higher carbohydrate breakfast meals on cardiometabolic risk

Read More

Cardiovascular Safety of Oral Semaglutide in Patients with Type 2 Diabetes

Aug 22, 2019

Cardiovascular Safety of Oral Semaglutide in Patients with Type 2 Diabetes By Heather Nelson Cortes, PhD and Kevin C Maki, PhD Cardiovascular disease (CVD) is the leading cause of mortality in patients with type 2 diabetes (T2D), therefore it is required that all new glucose-lowering therapies demonstrate no increase in cardiovascular risk with treatment.1  Glucagon-like-peptide-1

Read More

The Effects of Nutritional Supplements and Dietary Interventions on All-Cause Mortality and Cardiovascular Outcomes

Aug 12, 2019

The Effects of Nutritional Supplements and Dietary Interventions on All-Cause Mortality and Cardiovascular Outcomes By Aly Becraft, MS and Kevin C Maki, PhD   Despite scientific uncertainty surrounding the benefits of dietary supplements, many U.S. adults use them, along with various dietary interventions, with the belief that they will improve their overall health (1).  Khan

Read More

Therapeutic potential of selective peroxisome proliferator-activated receptor alpha modulators (SPPARMα) for management of patients with atherogenic dyslipidemia

Jul 10, 2019

Therapeutic potential of selective peroxisome proliferator-activated receptor alpha modulators (SPPARMα) for management of patients with atherogenic dyslipidemia By Heather Nelson Cortes, PhD and Kevin C Maki, PhD   Atherosclerotic cardiovascular disease (ASCVD) is associated with a significant public health burden around the world.  It is further exacerbated by chronic lifestyle-related diseases, such as visceral obesity,

Read More

Serum Markers of Oxidative Stress to Assess Mortality Risk in Patients with Type 2 Diabetes

Jul 10, 2019

Serum Markers of Oxidative Stress to Assess Mortality Risk in Patients with Type 2 Diabetes By Aly Becraft, MS and Kevin C Maki, PhD Hyperglycemia is thought to result in increased reactive oxygen species (ROS) production and weakened antioxidant capacity,1 which can make patients with type 2 diabetes (T2D) susceptible to elevated oxidative stress. Current

Read More

Sub-optimal cholesterol response to initiation of statins and future risk of cardiovascular disease

Jun 8, 2019

Sub-optimal cholesterol response to initiation of statins and future risk of cardiovascular disease By Heather Nelson Cortes, PhD and Kevin C Maki, PhD   Cardiovascular disease (CVD) continues to be the leading cause of death around the world and it is directly associated with blood levels of low-density lipoprotein cholesterol (LDL-C).1,2  In many clinical trials

Read More

Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy

May 29, 2019

Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy By Aly Becraft, MS and Kevin C Maki, PhD The Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) trial was designed to assess the effects of the sodium-glucose cotransporter 2 (SGLT2) inhibitor, canagliflozin, on renal outcomes in patients with type 2

Read More

Oral Semaglutide versus Sitagliptin on Glycated Hemoglobin in Adults With Type 2 Diabetes

May 27, 2019

Oral Semaglutide versus Sitagliptin on Glycated Hemoglobin in Adults With Type 2 Diabetes By Aly Becraft, MS and Kevin C Maki, PhD   The PIONEER3 trial was designed to compare the efficacy, long-term adverse event profile, and tolerability of an orally administered formulation of the glucagon-like peptide 1 receptor agonist (GLP-1RA), semaglutide, with the widely-used

Read More

Associations of Dietary Cholesterol and Egg Consumption with Incident Cardiovascular Disease and Total Mortality

May 2, 2019

Associations of Dietary Cholesterol and Egg Consumption with Incident Cardiovascular Disease and Total Mortality Associations of Dietary Cholesterol and Egg Consumption with Incident Cardiovascular Disease and Total Mortality   By Kevin C. Maki, PhD and Heather Nelson Cortes, PhD   Despite decades of research, the association between dietary cholesterol consumption, cardiovascular disease (CVD) and mortality

Read More